octocenter-logo

Adjuvant Pembrolizumab in Melanoma

Adjuvant Pembrolizumab in Melanoma

In the realm of melanoma treatment, adjunctive care is pivotal for addressing minuscule, lingering disease and diminishing the likelihood of a relapse following surgical removal. This therapy's primary aim is to enhance the chances of both overall and disease-free survival in individuals grappling with high-risk melanoma. For a considerable duration, interferon-alpha reigned as the go-to adjuvant treatment, yet its limited success rate and notable side effects have spurred the exploration of alternative therapies.

A key breakthrough in this quest is pembrolizumab, a notable inhibitor of the programmed cell death protein 1 (PD-1). This medication works by obstructing the PD-1 receptors found on T cells, thereby amplifying the body's immune defense against melanoma cells. Numerous clinical studies have substantiated pembrolizumab's efficacy in an adjuvant capacity.

This fact has garnered recognition and approval from health regulatory bodies for use in treating high-risk melanoma post-complete resection. Significantly, pembrolizumab has been shown to have markedly better distant metastasis-free survival and overall survival rates among these patients.

While there are some associated adverse reactions, they are typically manageable, and the drug is deemed to have a satisfactory safety profile. In essence, pembrolizumab's introduction into the adjuvant therapy landscape for melanoma represents a stride towards providing patients with a more productive and bearable treatment alternative aimed at curtailing disease recurrence and bolstering long-term health outcomes.

Pembrolizumab in Melanoma Treatment

Mechanism of Action

Pembrolizumab, a type of monoclonal antibody, functions as a focused inhibitor for the programmed cell death protein 1 (PD-1) receptor. It binds with PD-1, thereby blocking interaction with its ligands PD-L1 and PD-L2. This blockade paves the way for T cell activation and consequent immune responses against tumors. The antibody bolsters the cytotoxic T lymphocyte immune response, enabling these T cells to identify and destroy cancer cells. Pembrolizumab disrupts the PD-1/PD-L1 axis, reenergizing the immune system's capability to recognize and attack melanoma cells. This approach has shown its prowess in enhancing overall survival and stemming disease progression in patients with advanced or metastatic melanoma.

Clinical Efficacy

The clinical potency of Pembrolizumab in melanoma treatment has been proven in multiple researches. A phase III clinical trial, known as KEYNOTE-006, demonstrated Pembrolizumab's superior overall survival rates when compared to ipilimumab, a conventional treatment for advanced melanoma. This study targeted treatment-naive patients with inoperable or metastatic melanoma. Patients treated with Pembrolizumab displayed a median overall survival of 23.8 months versus 18.9 months in those treated with ipilimumab. Moreover, the objective response rate was significantly higher in the Pembrolizumab group (33.7%) as opposed to the ipilimumab group (11%). The KEYNOTE-002 phase II trial further substantiated this clinical efficacy, showing an objective response rate of 26.3% with Pembrolizumab in patients with ipilimumab-resistant melanoma.

Safety Profile

In terms of melanoma treatment, Pembrolizumab has demonstrated a relatively agreeable safety record. Fatigue, rash, itching, diarrhea, and nausea were some of the most frequently reported adverse occurrences in clinical trials. Most of these side effects were of mild to moderate intensity**. Immune-related adverse side effects (irAEs), such as hypothyroidism, pneumonitis, colitis, and hepatitis, were also reported**. Yet, severe (grade 3 or 4) irAEs were relatively rare. Serious adverse events were mostly due to immune-medicated events, but their occurrence was sparse and manageable with the correct intervention. Overall, the data pertaining to safety suggests that pembrolizumab is generally well-tolerated and presents a satisfactory risk-benefit profile for individuals with melanoma.

adjuvant pembrolizumab in melanoma

Adjuvant Pembrolizumab Trials

Key Study Designs

The study frameworks employed in adjuvant pembrolizumab trials are vital instruments in evaluating how effective this treatment modality is for patients suffering from melanoma. Randomized controlled trials (RCTs) have emerged as a widespread choice; these trials juxtapose adjuvant pembrolizumab with either standard treatments or placebos. All these trials adopt a future-forward approach in which participants are lumped together into various treatment cohorts haphazardly thus, minimizing bias and emphasizing that the differing outcomes are resultant of the evaluated treatment alone.

A handful of these studies even embrace blinded trials where both investigators and patients remain unaware of the participant's treatment allocation. This practice aims to further eliminate bias and ensure result authenticity. With the incorporation of these methodologies, the trials can assemble solid evidence in terms of the safety and efficacy of the adjuvant pembrolizumab which goes on to refine decision-making in clinical settings by enhancing patient outcomes in melanoma care.

Patient Selection Criteria

The selection of patients is a critical process that establishes eligibility for adjuvant pembrolizumab trails in melanoma. This is determined by a set of various factors, including the stage of the disease, the condition of the tumor, and the patient's overall health. Generally, Stage III melanoma patients, those with lymph node involvement, are sought out for this adjuvant treatment. There is a need for assessing the existence of factors that could prove detrimental to the patient's ability to undergo pembrolizumab treatment. Aspects such as prior treatments, organ function, and overall health are also taken into account. This selection process is designed to identify the patients who stand to reap maximum benefits from the adjuvant pembrolizumab while keeping potential risks at a minimum and optimizing treatment outcomes.

Treatment Regimens

Several treatment protocols have been the subject of clinical trials aimed at evaluating adjuvant pembrolizumab for melanoma patients. The regimen most widely studied involves administering pembrolizumab intravenously at intervals of three weeks, supplying a dose of 200 mg and extending to a full year. This dosage schedule has yielded significant results in decreasing disease relapse risk and enhancing overall patient survival post-surgical resection in high-risk melanoma patients.

Alternative regimens such as a higher 400 mg dose administered every six weeks, or pairing pembrolizumab with other immune checkpoint inhibitors or targeted therapies have also been explored. These trials seek to augment treatment outcomes and further improve patient outcomes, specifically those who may not respond as desired to the standard regimen. Understanding the best treatment regimens and their effects on patient outcomes is key to guiding clinical decision-making and customizing treatment for each patient.

Bibliography

  1. Long, G. V., Luke, J. J., Khattak, M. A., de la Cruz Merino, L., Del Vecchio, M., Rutkowski, P., ... & Ascierto, P. A. (2022). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 23(11), 1378-1388. (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00559-9/fulltext)

  2. Eggermont, A. M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., ... & Nathan, P. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The lancet oncology, 22(5), 643-654. (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00065-6/fulltext)

  3. Hamid, O., Robert, C., Daud, A., Carlino, M. S., Mitchell, T. C., Hersey, P., ... & Ribas, A. (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 157, 391-402. (https://www.sciencedirect.com/science/article/pii/S095980492100530X)

  4. Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021). Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy. Frontiers in Oncology. (https://www.frontiersin.org/articles/10.3389/fonc.2021.670726/full)

  5. Wagner, N. B., Lenders, M. M., Kühl, K., Reinhardt, L., André, F., Dudda, M., ... & Eigentler, T. K. (2021). Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. Journal for ImmunoTherapy of Cancer, 9(5). (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126291/)

  6. Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., ... & Ribas, A. (2022). Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma. Cancer discovery, 12(3), 644-653. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904282/)

  7. Carlino, M. S., Menzies, A. M., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., ... & Long, G. V. (2020). Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma: KEYNOTE-029 part 1B. Clinical Cancer Research, 26(19), 5086-5091. (https://aacrjournals.org/clincancerres/article-abstract/26/19/5086/82744)

  8. Robert, C., Carlino, M. S., McNeil, C., Ribas, A., Grob, J. J., Schachter, J., ... & Long, G. V. (2023). Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. Journal of Clinical Oncology, 41(24), 3998-4003. (https://www.ingentaconnect.com/content/wk/jco/2023/00000041/00000024/art00008)

  9. Bhave, P., Ahmed, T., Lo, S. N., Shoushtari, A., Zaremba, A., Versluis, J. M., ... & Carlino, M. S. (2022). Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. Journal for immunotherapy of cancer, 10(7). (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260790/)

  10. Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., ... & Mukhametshina, G. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 22(5), 655-664. (https://research.rug.nl/files/358617018/PIIS1470204521000814.pdf)

  11. Unger, J. M., Darke, A., Othus, M., Truong, T. G., Khushalani, N., Kendra, K., ... & Patel, S. P. (2023). Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA oncology, 9(2), 251-260. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685550/)